Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2019 09:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Kerry Wentworth, Chief Regulatory Officer, Appointed to Massachusetts Biotechnology Council Board

BURLINGTON, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics today announced that Kerry Wentworth, Chief Regulatory Officer, has been appointed to the Massachusetts Biotechnology...
March 04, 2019 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference

BURLINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will present at the...
March 01, 2019 16:45 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to five new employees for an aggregate of 19,250...
February 28, 2019 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results

Company reported net ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) sales of $22.5 million for full-year 2018Since launch, 90% of target accounts have purchased or received...
February 26, 2019 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the 40th Annual Raymond James Institutional Investors Conference

BURLINGTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be presenting at the 40th Annual Raymond James Institutional Investors...
February 21, 2019 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage

Study conducted in collaboration with MIT showed that triamcinolone acetonide had protective effects on inflamed and/or injured cartilage in an established preclinical modelData presented in “late...
February 20, 2019 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019

BURLINGTON, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2018 financial results after the...
February 11, 2019 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Rheumatology and Therapy

Results from Phase 3b clinical trial indicate that repeat administration of ZILRETTA for osteoarthritis (OA) knee pain was generally safe and well-toleratedX-ray data at baseline and Week 52 showed...
February 08, 2019 09:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12

BURLINGTON, Mass., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has been invited to ring the Nasdaq opening bell on Tuesday, February 12, 2019...
February 01, 2019 17:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to 14 new employees for an aggregate of 51,000...